| abstract |
The present invention relates to oncology, and specifically to a novel medicinal preparation and method for treating bone lesions caused by malignant neoplasms. In order to achieve the above, a medicinal preparation is proposed which is in the form of a lyophilizate for preparing a solution for parenteral administration and includes the following ingredients: a pharmaceutically acceptable salt of a divalent metal and 1-(((((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidine-1(2H)-yl)-3,4-dihydroxytetrahydro-furan-2-yl)methoxy)(hydroxy)phosphoryloxy)(hydroxy)phosphoryl)-1-hydroxyethyl phosphonic acid or a pharmaceutically acceptable salt thereof with a molar ratio of components ranging from 1:1 to 20:1. A treatment method involves introducing a solution of the medicinal preparation according to the invention, in the form of intravenous drip infusions, with a dose of between 0.01 and 5mg/kg of the active ingredient per 1kg of mass of the patient, in the form of intravenous drip infusions. Treatment using the medicinal preparation according to the invention allows for reducing the metabolic activity of bone lesions caused by malignant neoplasms by up to 100%. |